ECSP13012438A - Proceso para preparar compuestos antivirales - Google Patents

Proceso para preparar compuestos antivirales

Info

Publication number
ECSP13012438A
ECSP13012438A ECSP13012438A ECSP13012438A EC SP13012438 A ECSP13012438 A EC SP13012438A EC SP13012438 A ECSP13012438 A EC SP13012438A EC SP13012438 A ECSP13012438 A EC SP13012438A
Authority
EC
Ecuador
Prior art keywords
antiviral compounds
salts
compound
prepare antiviral
prepare
Prior art date
Application number
Other languages
English (en)
Inventor
Anthony R Haight
David Barnes
Shashank Shekhar
Thaddeus S Franczyk
Travis B Dunn
Vincent S Chan
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45467152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012438(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of ECSP13012438A publication Critical patent/ECSP13012438A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2419—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member
    • B01J31/2423—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member comprising aliphatic or saturated rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/30—Addition reactions at carbon centres, i.e. to either C-C or C-X multiple bonds
    • B01J2231/34—Other additions, e.g. Monsanto-type carbonylations, addition to 1,2-C=X or 1,2-C-X triplebonds, additions to 1,4-C=C-C=X or 1,4-C=-C-X triple bonds with X, e.g. O, S, NH/N
    • B01J2231/341—1,2-additions, e.g. aldol or Knoevenagel condensations
    • B01J2231/342—Aldol type reactions, i.e. nucleophilic addition of C-H acidic compounds, their R3Si- or metal complex analogues, to aldehydes or ketones
    • B01J2231/344—Boronation, e.g. by adding R-B(OR)2
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B01J2231/42—Catalytic cross-coupling, i.e. connection of previously not connected C-atoms or C- and X-atoms without rearrangement
    • B01J2231/4205—C-C cross-coupling, e.g. metal catalyzed or Friedel-Crafts type
    • B01J2231/4211—Suzuki-type, i.e. RY + R'B(OR)2, in which R, R' are optionally substituted alkyl, alkenyl, aryl, acyl and Y is the leaving group
    • B01J2231/4227—Suzuki-type, i.e. RY + R'B(OR)2, in which R, R' are optionally substituted alkyl, alkenyl, aryl, acyl and Y is the leaving group with Y= Cl
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B01J2231/42—Catalytic cross-coupling, i.e. connection of previously not connected C-atoms or C- and X-atoms without rearrangement
    • B01J2231/4277—C-X Cross-coupling, e.g. nucleophilic aromatic amination, alkoxylation or analogues
    • B01J2231/4283—C-X Cross-coupling, e.g. nucleophilic aromatic amination, alkoxylation or analogues using N nucleophiles, e.g. Buchwald-Hartwig amination
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B01J2231/42—Catalytic cross-coupling, i.e. connection of previously not connected C-atoms or C- and X-atoms without rearrangement
    • B01J2231/4277—C-X Cross-coupling, e.g. nucleophilic aromatic amination, alkoxylation or analogues
    • B01J2231/4288—C-X Cross-coupling, e.g. nucleophilic aromatic amination, alkoxylation or analogues using O nucleophiles, e.g. alcohols, carboxylates, esters
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B01J2231/42—Catalytic cross-coupling, i.e. connection of previously not connected C-atoms or C- and X-atoms without rearrangement
    • B01J2231/4277—C-X Cross-coupling, e.g. nucleophilic aromatic amination, alkoxylation or analogues
    • B01J2231/4294—C-X Cross-coupling, e.g. nucleophilic aromatic amination, alkoxylation or analogues using S nucleophiles, e.g. thiols
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Se divulgan: (a) procesos para preparar un compuesto y sales del mismo que, entre otras aplicaciones, son útiles para inhibir el virus de hepatitis C (HCV); (b) intermediarios útiles en la preparación del compuesto y sales; (c) composiciones farmacéuticas que comprenden el compuesto o sales; y (d) métodos para usar dichas composiciones.
ECSP13012438 2010-07-16 2013-02-13 Proceso para preparar compuestos antivirales ECSP13012438A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36529310P 2010-07-16 2010-07-16
US201161444475P 2011-02-18 2011-02-18

Publications (1)

Publication Number Publication Date
ECSP13012438A true ECSP13012438A (es) 2013-06-28

Family

ID=45467152

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012438 ECSP13012438A (es) 2010-07-16 2013-02-13 Proceso para preparar compuestos antivirales

Country Status (23)

Country Link
US (1) US8895737B2 (es)
EP (3) EP2593439B1 (es)
JP (2) JP5819959B2 (es)
KR (1) KR101893751B1 (es)
CN (2) CN105622525B (es)
AU (1) AU2011278927B2 (es)
BR (1) BR112013001132A2 (es)
CA (1) CA2805748A1 (es)
CL (2) CL2013000159A1 (es)
CO (1) CO6670583A2 (es)
CR (2) CR20180412A (es)
DO (1) DOP2013000017A (es)
EA (2) EA201790723A1 (es)
EC (1) ECSP13012438A (es)
GT (1) GT201300021A (es)
IL (1) IL224222A (es)
MX (2) MX344148B (es)
MY (1) MY167881A (es)
NZ (2) NZ605767A (es)
PE (1) PE20131086A1 (es)
SG (2) SG187102A1 (es)
UA (1) UA115025C2 (es)
WO (1) WO2012009699A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115025C2 (uk) * 2010-07-16 2017-09-11 Еббві Айрленд Анлімітед Компані Спосіб одержання противірусних сполук
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
BR112013001138A2 (pt) 2010-07-16 2016-07-05 Abbvie Inc ligantes de fosfina para reações catalíticas
US9255074B2 (en) * 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
AU2012234259A1 (en) * 2011-03-31 2013-10-03 Libera-Korner, Jeanette Perfluorinated compounds for the non-viral transfer of nucleic acids
CN104884440A (zh) * 2012-08-21 2015-09-02 艾伯维公司 用于制备抗病毒化合物的方法
WO2015038596A1 (en) 2013-09-11 2015-03-19 Emory University Nucleotide and nucleoside compositions and uses related thereto
WO2016054240A1 (en) 2014-09-30 2016-04-07 Sean Dalziel Fixed dose combinations for the treatment of viral diseases
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
CN108290844B (zh) * 2016-05-27 2021-04-30 深圳市塔吉瑞生物医药有限公司 一种取代的萘环化合物及药物组合物及其应用
CN110201714B (zh) * 2019-07-04 2022-07-29 蚌埠学院 二氢嘧啶酮类化合物合成方法及催化剂
CN110669006A (zh) * 2019-10-22 2020-01-10 中国科学技术大学 茚并异喹啉类化合物及其制备方法
CN112735799B (zh) * 2020-12-10 2022-12-20 华东理工大学 一种新型磁性材料及其制备方法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
US4731472A (en) 1986-03-03 1988-03-15 Merck & Co., Inc. (5,6-dichloro-3-oxo-9A-propyl-2,3,9,9A-tetrahydrofluoren-7-yl)alkanoic acids and alkanimidamides
US4873238A (en) 1988-09-19 1989-10-10 American Home Products Corporation 2-Pyridinecarbothioamides and pharmaceutical compositions comprising the same
US4958023A (en) 1988-09-19 1990-09-18 American Home Products Corporation 2-pyridinecarbothioamides, processes for preparation thereof and pharmaceutical compositions comprising the same
US5084084A (en) 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
AU627906B2 (en) 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
ATE169915T1 (de) 1990-02-15 1998-09-15 Takeda Chemical Industries Ltd Pyrimidindionderivate, deren herstellung und verwendung
NL9001075A (es) 1990-05-04 1991-12-02 Duphar Int Res
WO1992009545A2 (en) 1990-11-21 1992-06-11 Massachusetts Institute Of Technology New methods for the catalytic reduction of organic substrates
US5489682A (en) 1990-11-21 1996-02-06 Massachusetts Institute Of Technology Catalytic asymmetric reduction of enamines
ES2116435T3 (es) 1992-01-31 1998-07-16 Hoffmann La Roche Ligandos difosfinicos.
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
JP3345476B2 (ja) 1993-05-18 2002-11-18 株式会社東芝 有機非線形光学材料
IT1264813B1 (it) 1993-07-28 1996-10-10 Oxon Italia Spa Procedimento per la preparazione di alcansolfonammidi
DK0647648T3 (da) 1993-10-08 1999-09-27 Hoffmann La Roche Optisk aktive phosphorforbindelser
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
US6231783B1 (en) 1995-11-14 2001-05-15 Massachusetts Institute Of Technology Replacement solvents for use in chemical synthesis
US6031105A (en) 1996-04-09 2000-02-29 Pfizer Inc Substituted pyridines
US5847166A (en) 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
US6242616B1 (en) 1996-12-03 2001-06-05 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US5789605A (en) 1996-12-03 1998-08-04 Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof
US6096904A (en) 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US20050065353A1 (en) 1996-12-03 2005-03-24 Smith Amos B. Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
US6870058B2 (en) 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
US6395939B1 (en) 1997-10-06 2002-05-28 Massachusetts Institute Of Technology Diaryl ether condensation reactions
US6867310B1 (en) 1997-11-20 2005-03-15 Massachusetts Institute Of Technology Arylation and vinylation of activated carbons
WO1999028290A1 (en) 1997-12-03 1999-06-10 Massachusetts Institute Of Technology Synthesis of oligoarylamines, and uses and reagents related thereto
JP4647780B2 (ja) 1998-02-26 2011-03-09 マサチューセッツ インスティテュート オブ テクノロジー ヒドラジン、ヒドラゾン、ヒドロキシルアミンおよびオキシムの金属−触媒アリール化およびビニル化
DK1097158T3 (da) 1998-07-10 2006-05-29 Massachusetts Inst Technology Ligander til metaller og metalkatalyserede metoder
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
DE19920847A1 (de) 1999-05-06 2000-11-09 Clariant Gmbh Pd- und Ni-Komplexe von Biphenyl-2-yl-phosphanen und ihre Anwendung in katalytischen C,C-,N- und C,O-Kupplungen
US6465664B1 (en) 1999-09-15 2002-10-15 Massachusetts Institute Of Technology Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems
JP2003514913A (ja) 1999-11-24 2003-04-22 マサチューセッツ インスティテュート オブ テクノロジー 多糖、天然生成物及びコンビナトリアル・ライブラリの合成に有用な保護基
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
PT1237878E (pt) 1999-12-06 2007-06-18 Hoffmann La Roche 4-pirimidinil-n-acil-fenilalaninas
IL167958A (en) 2000-02-04 2010-11-30 Sumitomo Chemical Co 2-thio 3-hydroxypyridine derivatives
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6624159B2 (en) 2000-07-12 2003-09-23 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
DK1390340T3 (en) 2001-04-24 2017-05-15 Massachusetts Inst Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
CA2446716A1 (en) * 2001-06-05 2002-12-12 Eli Lilly And Company Sulfonamide derivatives
CA2456553A1 (en) 2001-08-07 2003-02-20 Amos B. Smith, Iii Compounds which mimic the chemical and biological properties of discodermolide
DE10162700A1 (de) * 2001-12-19 2003-07-03 Merck Patent Gmbh Dioxathianone
US20030207877A1 (en) 2001-12-20 2003-11-06 Strohbach Joseph Walter Pyridoquinoxaline antivirals
AU2003217232A1 (en) 2002-02-04 2003-09-02 Massachusetts Institute Of Technology Transition-metal-catalyzed carbon-nitrogen bond-forming methods using carbene ligands
ITMI20020415A1 (it) 2002-03-01 2003-09-01 Chemi Spa Catalizzatori metallici per reazione chemo- regio- stereo-selettive erelativi precursori
EP1534671A4 (en) 2002-08-02 2007-10-24 Massachusetts Inst Technology FORMATION OF CARBON-HETEROATOME AND CARBON-CARBON BONDS CATALYZED WITH COPPER
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
US20050113450A1 (en) 2002-08-23 2005-05-26 Atli Thorarensen Antibacterial agents
US20040142981A1 (en) 2002-08-23 2004-07-22 Atli Thorarensen Antibacterial benzoic acid derivatives
US7208490B2 (en) 2002-10-07 2007-04-24 Pharmacia & Upjohn Company Llc Tricyclic tetrahydroquinoline antibacterial agents
US20040097492A1 (en) * 2002-11-01 2004-05-20 Pratt John K Anti-infective agents
EP1581467B1 (en) 2002-12-09 2016-10-12 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
CA2548518A1 (en) 2003-12-04 2005-07-07 Wyeth Biaryl sulfonamides as mmp inhibitors
WO2005065683A1 (en) 2003-12-22 2005-07-21 Eli Lilly And Company Triazole, oxadiazole and thiadiazole derivative as ppar modulators for the treatment of diabetes
ES2308562T3 (es) 2004-11-10 2008-12-01 Pfizer, Inc. Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos.
SE0403006D0 (sv) 2004-12-09 2004-12-09 Biovitrum Ab New compounds
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
CN101080411B (zh) 2004-12-17 2011-11-02 伊莱利利公司 作为mch受体拮抗剂的噻唑并吡啶酮衍生物
JP5244399B2 (ja) 2005-01-10 2013-07-24 マサチューセッツ インスティテュート オブ テクノロジー 遷移金属を触媒とする炭素−窒素結合および炭素−炭素結合形成反応
JP4906839B2 (ja) 2005-03-10 2012-03-28 ファイザー株式会社 置換ｎ−スルホニルアミノフェニルエチル−２−フェノキシアセトアミド化合物
CA2601508C (en) 2005-03-17 2012-01-03 Pfizer, Inc. Cyclopropanecarboxamide derivatives
WO2007133637A2 (en) 2006-05-10 2007-11-22 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
CN104628655A (zh) * 2007-09-17 2015-05-20 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
CA2699981C (en) * 2007-09-17 2017-08-22 Abbott Laboratories Uracil or thymine derivative for treating hepatitis c
PT2203430E (pt) 2007-09-17 2011-09-02 Abbott Lab N-fenildioxohidropirimidinas úteis como inibidores do vírus da hepatite c (vhc)
EP2231680B1 (en) 2007-12-12 2018-03-28 Massachusetts Institute of Technology Ligands for transition-metal-catalyzed cross-couplings, and methods of use thereof
BRPI0916233A2 (pt) 2008-07-23 2018-03-13 F.Hoffman-La Roche Ag compostos heterocíclicos antivirais
EP2184273A1 (de) 2008-11-05 2010-05-12 Bayer CropScience AG Halogen-substituierte Verbindungen als Pestizide
JP5326510B2 (ja) 2008-11-11 2013-10-30 セントラル硝子株式会社 α−置換エステル類の製造方法
ES2488821T3 (es) 2009-03-24 2014-08-29 Abbvie Bahamas Ltd. Proceso de preparación de un compuesto antiviral
AU2010264802A1 (en) 2009-06-24 2012-01-19 F. Hoffmann-La Roche Ag Heterocyclic antiviral compound
US20110005533A1 (en) 2009-07-07 2011-01-13 Evans Douglas J Mold For a Smoking Device
WO2011008725A2 (en) 2009-07-13 2011-01-20 Massachusetts Institute Of Technology Metal-catalyzed carbon-fluorine bond formation
WO2011008618A1 (en) 2009-07-13 2011-01-20 National University Of Singapore Metal-catalyzed carbon-fluorine bond formation
AR079170A1 (es) 2009-12-10 2011-12-28 Lilly Co Eli Compuesto de ciclopropil-benzamida-imidazo-benzazepina inhibidor de diacil-glicerol aciltransferasa, sal del mismo, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de obesidad o para mejorar la sensibilidad a insulina y compuesto intermedio par
CA2781888C (en) 2009-12-11 2019-06-18 Nono Inc. Agents and methods for treating ischemic and other diseases
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
FR2958289B1 (fr) 2010-03-30 2012-06-15 Sanofi Aventis Procede de preparation de derives de 3-ceto-benzofurane
WO2011133795A2 (en) 2010-04-22 2011-10-27 The Brigham And Women's Hospital, Inc. Beta-carbolines as inhibitors of haspin and dyrk kinases
US8980929B2 (en) 2010-05-21 2015-03-17 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
BR112013001138A2 (pt) 2010-07-16 2016-07-05 Abbvie Inc ligantes de fosfina para reações catalíticas
UA115025C2 (uk) * 2010-07-16 2017-09-11 Еббві Айрленд Анлімітед Компані Спосіб одержання противірусних сполук

Also Published As

Publication number Publication date
CN103097360A (zh) 2013-05-08
EP3056486B1 (en) 2018-07-11
US20120014913A1 (en) 2012-01-19
CL2016000382A1 (es) 2016-11-04
NZ605767A (en) 2015-04-24
CO6670583A2 (es) 2013-05-15
PE20131086A1 (es) 2013-10-24
EP3056486A3 (en) 2016-09-14
WO2012009699A3 (en) 2012-03-15
CL2013000159A1 (es) 2013-10-04
CN105622525B (zh) 2019-02-15
JP6162191B2 (ja) 2017-07-12
EP2593439B1 (en) 2016-08-17
NZ705225A (en) 2016-11-25
KR20130043195A (ko) 2013-04-29
EP3415504A1 (en) 2018-12-19
US8895737B2 (en) 2014-11-25
SG10201505540SA (en) 2015-08-28
JP2016041699A (ja) 2016-03-31
GT201300021A (es) 2014-09-26
AU2011278927A1 (en) 2013-01-31
EA201790723A1 (ru) 2017-12-29
AU2011278927B2 (en) 2015-05-21
MX344148B (es) 2016-12-07
EP2593439A2 (en) 2013-05-22
CN103097360B (zh) 2016-02-10
MX2013000623A (es) 2013-06-13
KR101893751B1 (ko) 2018-09-03
EP3056486A2 (en) 2016-08-17
JP5819959B2 (ja) 2015-11-24
JP2013532636A (ja) 2013-08-19
SG187102A1 (en) 2013-02-28
CR20130054A (es) 2013-04-17
EA028082B1 (ru) 2017-10-31
MY167881A (en) 2018-09-26
CR20180412A (es) 2018-11-01
EA201390130A1 (ru) 2013-06-28
BR112013001132A2 (pt) 2016-05-17
IL224222A (en) 2016-08-31
UA115025C2 (uk) 2017-09-11
CA2805748A1 (en) 2012-01-19
CN105622525A (zh) 2016-06-01
DOP2013000017A (es) 2013-03-15
WO2012009699A2 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
ECSP13012438A (es) Proceso para preparar compuestos antivirales
UY33897A (es) Inhibidores del virus de la hepatitis c
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
CO6561783A2 (es) Inhibidores del virus flaviviridae
BR112013028487A2 (pt) inibidores do vírus da hepatite c
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
ECSP14013189A (es) Inhibidores de la replicación de los virus de la gripe
UY34066A (es) Inhibidores del virus de la hepatitis c
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
AR089578A1 (es) Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion
PE20230684A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
BR112013002729A2 (pt) inibidores de vírus de hepatite c
CL2017000293A1 (es) Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014)
BR112013032049A2 (pt) inibidores do vírus da hepatite c
BR112014013972A2 (pt) inibidores de hcv nssa
EA201590770A1 (ru) Ингибиторы вируса гепатита с
CR20110524A (es) Proceso para preparar compuestos antivirales
CL2014000394A1 (es) Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.
MX360161B (es) Proceso para preparar compuestos antiviricos.
AR086987A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
BR112014015582A8 (pt) compostos antivirais
UA113048C2 (xx) Противірусні сполуки
CO6321231A2 (es) Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatitis c
TN2013000135A1 (en) Solid state forms of a potent hcv inhibitor